Exozymes Inc EXOZ

$4.00 -0.60 (-13.04%)

Valuation

Market cap
42,709,000
Revenue TTM
$0
Net income TTM
$-9,160,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
24,350
Avg volume
6,650
Day's range
$3.70 – $4.88
Shares out
9,305,000
Stochastic %K
5%
Beta
3.19
Analysts
Hold
Price target
—

Price

Company profile

eXoZymes, Inc. operates as a development stage biotechnology company. It focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Technologies, Inc. and changed its name to eXoZymes, Inc. in February 2025. eXoZymes, Inc. was incorporated in 2014 and is headquartered in Monrovia, California.

Industry
Biotechnology
Sector
Healthcare
Phone
626 415 1488
Website
https://www.exozymes.com
Address
750 Royal Oaks Drive, Suite 106, Monrovia, United States

Latest news

Stocktwits

CcapLP Oct 9, 3:52 AM
$EXOZ This company is worth $0. They could barely close an equity raise, they cut size and price.
0 replies
eXoZymes Oct 8, 2:44 PM
eXoZymes CEO, Heltzen, was recently interviewed by Pix11 "Top Leaders" host, Nadja Atwal: Michael Heltzen is leading @eXoZymes in rethinking biomanufacturing. By harnessing enzymes and AI, the company aims to produce health ingredients faster, sustainably, and closer to home—reducing reliance on traditional supply chains while making previously inaccessible natural compounds available at scale. Full interview available here: https://na2.hubs.ly/H08gMKy0 $EXOZ
0 replies
eXoZymes Oct 7, 1:42 PM
Update from Slack Capital: What if eXoZymes’ biggest opportunity isn’t a single molecule, but an AI-powered engine that combines computational design with cell-free biomanufacturing to repeatedly turn previously inaccessible chemistry into new products - and then do it all over again? Read the full update from Slack Capital here: https://na2.hubs.ly/H08fjzV0 $EXOZ
0 replies
yes3 Oct 6, 10:27 PM
$EXOZ when will this company gain traction? Are revenues expected this year? Sorry i havent been keeping up. A summary of the past 6 months will be appreciated
1 replies
Slack_Capital Oct 6, 7:56 PM
What excites me most about @eXoZymes $EXOZ Genesis Mission project is where this work could ultimately lead to. https://slack-capital.com/p/exozymes-path-to-computational-biomanufacturing Working with Lawrence Berkeley National Laboratory, @eXoZymes is developing an AI-powered digital twin to predict how its cell-free enzymatic pathways perform under different operating conditions. Combining this model with @eXoZymes existing pathway design, enzyme selection and AI-driven enzyme optimisation capabilities, and a much more powerful development engine starts to emerge. Over time, @eXoZymes could computationally design much of the production process upfront, resulting in faster development timelines, fewer experimental cycles, lower costs and significantly more compounds progressing through the platform in parallel. All of which feeds directly back into the compounding flywheel I’ve continually referenced. https://exozymes.com/blog/genesis-mission-2026
0 replies
Slack_Capital Oct 2, 11:35 PM
$EXOZ What an interview! https://www.youtube.com/watch?v=IogiFk9cVe4 It just clicked what @eXoZymes $EXOZ is cooking here… eXoZymes is going to remain laser-focused on the Nutra and Pharma space. This market is enormous and the opportunity alone represents a monumental investment case. At the same time, eXoZymes’ recognises that its cell-free technology has obviously applications far beyond Nutra and Pharma. It has the potential to support cleaner biomanufacturing, enable new advanced chemicals and materials, and ultimately usher in a new industrial era. However, as Michael has continually stated, the challenge is having disciplined focus. eXoZymes can't realistically build and commercialise products across every industry. So for industries outside Nutra and Pharma, eXoZymes plans to license its core cell-free technology to companies that already specialise in those markets.
1 replies
OnlyFibs Sep 20, 1:13 AM
$EXOZ | Technical Setup 📉🧪 • Structure: $EXOZ coiling inside a multi-month falling wedge following a drop to major base support near $4.35–$5.00. Price is bouncing off lower channel support and compressing toward key horizontal volume shelf levels. • Catalyst: Synthetic biomanufacturing platform expansion and NIH grant funding advancing cannabinoid analog drug discovery programs. 🎯 Key Levels: 🐂 Bull Trigger: $6.70 / $10.25 🚀 Targets: $11.60 / $14.10 / $18.40 🛡️ Support: $6.00 / $5.00 ⚠️ Risk: $4.35 / $3.50 #EXOZ #stocks #trading #biotech #hovdid
0 replies
OnlyFibs Sep 17, 11:17 PM
$EXOZ | Fundamental & Technical Breakdown 📊🧪 • Business Overview: Development-stage synthetic biology company focused on enzymatic platforms for scalable biological molecule discovery. • Profitability & Financials: Unprofitable. Early-stage micro-cap company with no active commercial revenue, operating with net losses (~-$1.20 EPS). • Latest Earnings Report: Missed/Unprofitable (Reported EPS of -$0.33 with zero revenue). • Wall Street Analyst Consensus: Unrated / Low Coverage. Limited institutional analyst coverage given small market cap (~$57M). • Overall Bias: Cautiously Speculative / Bottoming Watch (Technicals compressing in a falling wedge near $6.10 support; breakout triggers above $7.50). Key Levels for Bulls & Bears: • Bull Reclaim Trigger: $7.50 / $8.20 • Overhead Targets: $9.10 / $10.15 • Critical Support Pivot: $6.10 • Bearish Invalidation Level: $5.90 / $4.35 #EXOZ #biotech #smallcaps #fundamentalanalysis #hovdid
0 replies